MedTrace Logo

Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection

NCT01844310 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2013-05-01

No results posted yet for this study

Summary

This study is to evaluate the safety and efficacy of RAL-based regimen in treatment-experienced patients with resistant HIV infection

Conditions

  • AIDS/HIV PROBLEM

Interventions

DRUG

RAL+TDF+LPV/r

Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).

DRUG

3TC+TDF+LPV/r

Group B will be assigned with 3TC+TDF+LPV/r

Sponsors & Collaborators

  • Peking Union Medical College

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01844310 on ClinicalTrials.gov